Literature DB >> 32387045

Liver Stereotactic Ablative Radiotherapy: an Effective and Feasible Alternative to Surgery during the COVID-19 Pandemic.

K Aitken1, J Good2, M Hawkins3, D Grose4, S Mukherjee5, M Harrison6, G Radhakrishna7.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32387045      PMCID: PMC7252179          DOI: 10.1016/j.clon.2020.04.012

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


× No keyword cloud information.
Madam — The COVID-19 pandemic is having an unprecedented impact on UK cancer services. Access to radical surgery has been severely restricted and resources for systemic therapy provision are being limited as the crisis unfolds. Radiotherapy resources are rightly being focused on patients being treated with curative intent. However, it is our experience that access to stereotactic ablative radiotherapy (SABR) is diminishing, predominantly due to staffing shortages. SABR offers a non-invasive, outpatient ablative approach with minimal hospital footfall and with lower immunosuppressive risks than chemotherapy. The recently published long-term outcomes of the SABR COMET study illustrate the ability of SABR to substantially impact survival across tumour types [1]. The NHS England Commissioning through Evaluation process has shown that SABR can be safely delivered in the UK [2,3]. SABR requires specialist multidisciplinary expertise. The majority of radiotherapy departments are planning to maintain their capacity for category 1–4 treatments [4] and many have therefore suspended SABR for oligometastatic disease. However, we are concerned that diminishing access to SABR, at a time when access to other curative local treatment modalities is already restricted, will result in poorer patient outcomes in the short and medium term when this need not be the case. Patients with liver-limited colorectal cancer have a 5-year survival of 40% following surgery [5]. Given the evidence supporting SABR for colorectal liver metastases [6], we believe that this should be prioritised if patients are unable to access surgery and interventional ablative techniques. Similarly, SABR should be considered for patients with hepatocellular carcinoma while access to other services (particularly transplant) is limited. We urge radiotherapy departments to preserve access to SABR for patients in these situations, particularly as the COVID-19 pandemic wanes and staffing levels allow the re-establishment of normal services.

Conflicts of interest

The authors declare no conflicts of interest.
  3 in total

1.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

2.  Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review.

Authors:  Fausto Petrelli; Tiziana Comito; Sandro Barni; Gianfranco Pancera; Marta Scorsetti; Antonio Ghidini
Journal:  Radiother Oncol       Date:  2018-07-09       Impact factor: 6.280

Review 3.  Colorectal Liver Metastases: A Critical Review of State of the Art.

Authors:  Robert P Jones; Norihiro Kokudo; Gunnar Folprecht; Yoshihiro Mise; Michiaki Unno; Hassan Z Malik; Stephen W Fenwick; Graeme J Poston
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

  3 in total
  4 in total

Review 1.  Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.

Authors:  Zahra Siavashpour; Neda Goharpey; Mosayyeb Mobasheri
Journal:  Crit Rev Oncol Hematol       Date:  2021-06-30       Impact factor: 6.312

Review 2.  Covid-19 and radiotherapy: a systematic review after 2 years of pandemic.

Authors:  Antonio Piras; Valeria Venuti; Andrea D'Aviero; Davide Cusumano; Stefano Pergolizzi; Antonino Daidone; Luca Boldrini
Journal:  Clin Transl Imaging       Date:  2022-07-23

Review 3.  The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era.

Authors:  Zheng Li; Yue Hu; Ming Zeng; Qinyong Hu; Fei Ye; Ruifeng Liu; Hongyi Cai; Qiang Li; Xiaohu Wang
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

4.  Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.

Authors:  Zheng Li; Qiang Li; Xiaohu Wang; Sha Li; Weiqiang Chen; Xiaodong Jin; Xinguo Liu; Zhongying Dai; Xiongxiong Liu; Xiaogang Zheng; Ping Li; Hui Zhang; Qiuning Zhang; Hongtao Luo; Ruifeng Liu
Journal:  Front Public Health       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.